Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 30 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

    Rochester, MN, Jacksonville, FL

  2. A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    Jacksonville, FL, Rochester, MN

  4. CTX131 in Relapsed/Refractory Hematologic Malignancies

    Scottsdale/Phoenix, AZ

  5. A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of BMS-986393 In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  7. KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome

    Rochester, MN

  8. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

    Jacksonville, FL, Rochester, MN

  10. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

.

Mayo Clinic Footer